BBS-Bioactive Bone Substitutes Oyj
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBONE, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot… Read more
BBS-Bioactive Bone Substitutes Oyj (BONEH) - Total Assets
Latest total assets as of June 2024: €9.37 Million EUR
Based on the latest financial reports, BBS-Bioactive Bone Substitutes Oyj (BONEH) holds total assets worth €9.37 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BBS-Bioactive Bone Substitutes Oyj - Total Assets Trend (2014–2023)
This chart illustrates how BBS-Bioactive Bone Substitutes Oyj’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BBS-Bioactive Bone Substitutes Oyj - Asset Composition Analysis
Current Asset Composition (December 2023)
BBS-Bioactive Bone Substitutes Oyj's total assets of €9.37 Million consist of 19.0% current assets and 81.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 18.6% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €7.69 Million | 72.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2023)
This chart illustrates how BBS-Bioactive Bone Substitutes Oyj's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BBS-Bioactive Bone Substitutes Oyj's current assets represent 19.0% of total assets in 2023, an increase from 1.2% in 2014.
- Cash Position: Cash and equivalents constituted 18.6% of total assets in 2023, up from 1.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 72.5% of total assets.
BBS-Bioactive Bone Substitutes Oyj Competitors by Total Assets
Key competitors of BBS-Bioactive Bone Substitutes Oyj based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
BBS-Bioactive Bone Substitutes Oyj - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BBS-Bioactive Bone Substitutes Oyj generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BBS-Bioactive Bone Substitutes Oyj is currently not profitable relative to its asset base.
BBS-Bioactive Bone Substitutes Oyj - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.39 | 0.96 | 0.47 |
| Quick Ratio | 0.39 | 0.96 | 0.47 |
| Cash Ratio | 0.00 | 0.78 | 0.00 |
| Working Capital | €-1.41 Million | € -82.00K | € -729.98K |
BBS-Bioactive Bone Substitutes Oyj - Advanced Valuation Insights
This section examines the relationship between BBS-Bioactive Bone Substitutes Oyj's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | €10.61 Million |
| Market Capitalization | $854.55K USD |
Valuation Analysis
Below Book Valuation: The market values BBS-Bioactive Bone Substitutes Oyj's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: BBS-Bioactive Bone Substitutes Oyj's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BBS-Bioactive Bone Substitutes Oyj (2014–2023)
The table below shows the annual total assets of BBS-Bioactive Bone Substitutes Oyj from 2014 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €10.61 Million | -0.70% |
| 2022-12-31 | €10.69 Million | +1.73% |
| 2021-12-31 | €10.51 Million | -17.22% |
| 2020-12-31 | €12.69 Million | +29.09% |
| 2019-12-31 | €9.83 Million | -11.86% |
| 2018-12-31 | €11.16 Million | +15.24% |
| 2017-12-31 | €9.68 Million | -24.38% |
| 2016-12-31 | €12.80 Million | +2.79% |
| 2015-12-31 | €12.45 Million | +5.72% |
| 2014-12-31 | €11.78 Million | -- |